Sera Presentation for Citi Healthcare Conference

Salt Lake City – February 17, 2022 – Sera Inc., The Pregnancy
Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors and patients,
today announced that its presentation at the virtual Citi 2022 Healthcare
Conference: Services, MedTech, Life Science Tools & HCIT, to be held February
23-24, 2022, has been rescheduled. Gregory C. Critchfield, M.D., M.S., Chairman
and CEO, will provide a company update and discuss Sera’s latest achievements.
Sera’s management will also be available for one-on-one meetings with
investors.

Citi 2022 Healthcare Conference: Services, MedTech, Life Science Tools &
HCIT
Sera’s management will participate in a Citi fireside chat on Thursday, February
24, 2022 that has been rescheduled to begin at 9:30 a.m. EST. A live webcast of
the company’s presentation will be available on the Investors section of the Sera
Prognostics website. A webcast replay will not be available.

About Sera, Inc.
Sera is a leading health diagnostics company dedicated to
improving the lives of women and babies through precision pregnancy care.
Sera’s mission is to deliver early, pivotal information in pregnancy to physicians,
enabling them to improve the health of their patients, resulting in reductions in
the costs of healthcare delivery. Sera has a robust pipeline of innovative
diagnostic tests focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera’s precision medicine PreTRM ® Test reports to a
physician the individualized risk of spontaneous premature delivery in a
pregnancy, enabling earlier proactive interventions in women with higher risk.
Sera is located in Salt Lake City, Utah.

About Preterm Birth
Preterm birth is defined as any birth before 37 weeks’ gestation and is the
leading cause of illness and death in newborns. The 2021 March of Dimes Report

Card shows that more than one in ten infants is born prematurely. Prematurity is
associated with a significantly increased risk of major long-term medical
complications, including learning disabilities, cerebral palsy, chronic respiratory
illness, intellectual disability, seizures, and vision and hearing loss, and can
generate significant costs throughout the lives of affected children. The annual
health care costs to manage short- and long-term complications of prematurity in
the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM ^® Test
The PreTRM ^® test is the only broadly validated, commercially available blood-
based biomarker test that provides an early, accurate and individualized risk
prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
The PreTRM^® test measures and analyzes proteins in the blood that are highly
predictive of preterm birth. The PreTRM ^® test permits physicians to identify,
during the 19th or 20th week of pregnancy, which women are at increased risk
for preterm birth, enabling more informed, personalized clinical decisions based
on each woman’s individual risk. The PreTRM ^® test is ordered by a medical
professional.
Sera, the Sera logo, The Pregnancy Company, and
PreTRM are trademarks or registered trademarks of Sera, Inc. in the
United States and/or other countries.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the Company’s planned presentations and one-on-one meetings with
investors at the aforementioned investor conference; and the company’s
strategic directives under the caption “About Sera, Inc.” These
“forward-looking statements” are based on management’s current expectations
of future events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set forth in or
implied by forward-looking statements. These risks and uncertainties include, but
are not limited to: net losses, cash generation, and the potential need to raise
more capital; revenues from the PreTRM test representing substantially all
Company revenues to date; the need for broad scientific and market acceptance
of the PreTRM test; a concentrated number of material customers; our ability to
introduce new products; potential competition; our proprietary biobank; critical
suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as
well as the business or operations of third parties with whom we conduct

business; estimates of total addressable market opportunity and forecasts of
market growth; potential third-party payer coverage and reimbursement; new
reimbursement methodologies applicable to the PreTRM test, including new CPT
codes and payment rates for those codes; changes in FDA regulation of
laboratory-developed tests; the intellectual property rights protecting our tests
and market position; and other factors discussed under the heading “Risk
Factors” contained in our Final Prospectus on Form S-1, which was filed with the
Securities and Exchange Commission on July 14, 2021, as well as any updates to
those risk factors filed from time to time in our Quarterly Reports on Form 10-Q,
Annual Reports on Form 10-K, or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and the Company undertakes
no duty to update this information unless required by law.

Investor Contact
Peter DeNardo, CapComm Partners
peter@capcommpartners.com
+1 (415) 389-6400

Media Contact
Erich Sandoval, Lazar FINN
Erich.sandoval@finnpartners.com
+1 (917) 497-2867